您好,欢迎来到化工原料网! [登录] [免费注册]
化工原料网
位置:首页 > 产品库 > Isavuconazole-d4
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Isavuconazole-d4
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Isavuconazole-d4图片
CAS NO:1346598-58-0
包装:1mg
市场价:2250元

产品介绍
Isavuconazole D4 (BAL-4815 D4) 是一种氘标记的 Isavuconazole (BAL-4815)。
Cas No.1346598-58-0
别名爱莎康唑-D4,BAL-4815-d4; RO-0094815-d4
Canonical SMILESFC(C=CC(F)=C1)=C1[C@](CN2N=CN=C2)(O)[C@@H](C)C3=NC(C4=C([2H])C([2H])=C(C#N)C([2H])=C4[2H])=CS3
分子式C22H13D4F2N5OS
分子量441.5
溶解度Acetonitrile: soluble
储存条件Store at -20°C
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述

Isavuconazole-d4is intended for use as an internal standard for the quantification of isavuconazole by GC- or LC-MS. Isavuconazole is a broad-spectrum triazole antifungal agent.1It inhibits the growth of clinical isolates ofA. fumigatus,A. terreus,A. flavus, andA. lentulus(MIC90s = 0.39, 0.39, 2, and 0.25 mg/L, respectively) as well asC. albicans,C. krusei, andC. parapsilosis(MIC50s = 0.03, 0.06, and 0.03 mg/L, respectively).1,2,3,4Isavuconazole also inhibits the growth of several other fungal species, including clinical isolates ofC. neoformansandC. gattii(MIC90s = 0.032 and 0.125 mg/L, respectively).1,3Formulations containing isavuconazole have been used in the treatment of invasive aspergillosis and mucormycosis.

1.Yamazaki, T., Inagaki, Y., Fujii, T., et al.In vitro activity of isavuconazole against 140 reference fungal strains and 165 clinically isolated yeasts from JapanInt. J. Antimicrob. Agents36(4)324-331(2010) 2.Rudramurthy, S.M., Chakrabarti, A., Geertsen, E., et al.In vitro activity of isavuconazole against 208 Aspergillus flavus isolates in comparison with 7 other antifungal agents: Assessment according to the methodology of the European Committee on Antimicrobial Susceptibility TestingDiagn. Microbiol. Infect. Dis.71(4)370-377(2011) 3.Datta, K., Rhee, P., Byrnes, E., III, et al.Isavuconazole activity against Aspergillus lentulus, Neosartorya udagawae, and Cryptococcus gattii, emerging fungal pathogens with reduced azole susceptibilityJ. Clin. Microbiol.51(9)3090-3093(2013) 4.Astvad, K.M.T., Hare, R.K., and Arendrup, M.C.Evaluation of the in vitro activity of isavuconazole and comparator voriconazole against 2635 contemporary clinical Candida and Aspergillus isolatesClin. Microbiol. Infect.23(11)882-887(2017)